Latest Regulatory Progress News

Freehill Mining has raised $1.5 million through a discounted share placement to fund exploration of copper-gold projects in Chile and expand its processing capacity.

Reef Casino Trust has issued a second supplementary target’s statement as the takeover bid by Iris Cairns Property Pty Ltd extends to August 2026 due to delayed casino licensing approvals. The board maintains its recommendation for unitholders to accept the offer, pending regulatory outcomes and expert advice.

Everlast Minerals has officially received the demarcated Kurigram site from the Bangladesh Government, clearing the way for exploration on a 4,000-hectare mineral sands licence area.

Bio-Gene Technology Limited reports strong progress in toxicology studies for Flavocide, targeting its first regulatory submission in Australia by March 2027. This milestone sets the stage for global registrations of the novel insecticide with a new mode of action.

Jade Gas Holdings has completed its appraisal program for the TTCBM Project in Mongolia, setting the stage for regulatory approvals and commercial development of a major domestic gas resource.

Many Peaks Limited has expanded the gold mineralisation strike at its Ferké Gold Project in Côte d’Ivoire to more than 1.1 kilometres, supported by strong assay results from recent drilling campaigns. This advancement highlights the potential for a significant increase in resource volume and open-pit reserve conversion at the Ouarigue prospect.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.

Firebrick Pharma reports a reduced half-year loss of $1.26 million while launching its Nasodine Throat Spray in Singapore and Fiji, with regulatory approval pending in the Philippines.